I'd been mulling over wether to send in some Qs I had or leave, but I thought theres no harm in simply asking a Q about the latest posters, so this is what I had put forward, and when I get a response, Ill post it here.
Email to Alterity:
On review of the latest poster and data information from the MSA congress meeting. I have noticed new information has been added regarding the number of patients with MSA-P.
With the 75mg cohort containing 70.8% of MSA-P patients (17/24); 50mg - 60% (14/25); and the placebo cohort with 59.1% (14/24).
Given information from the first release several weeks back, it was highlighted that the 75mg cohort at 12- 13 weeks had a 60% improvement/stabilisation rate but then levelled off to remain at a 30% improvement over the 52-week trial.
Given the larger percentage of patients in the 75mg cohort with MSA-P, were there significant differences between the remaining 29.2% (7 patients with MSA-C) ?.
Did the difference and large percentage of MSA-P patients cause the results to fall compared to MSA-C ?. Or did the 7 MSA-C patients keep the percentage higher ?.
Were the improvements seen across the board from MSA-C patients mainly ? or did both MSA-P and MSA-C patients see improvements ?.
Will the company be releasing individual results for better clarity and understanding/scrutiny ?.
Given previous attempts by other studies with iron chelating drugs to treat iron-related diseases, which had worsened neurodegenerative disease outcomes, does the company believe that initial dosing will commence at 75mg for the initial 12-13 weeks of potential treatment, then be reduced to 50mg ?.
(20min delay)